来源：Gangtise投研

　　药明生物（02269.HK）2024年度业绩电话会：2024年药明生物业绩稳健增长，收益达186.8亿元人民币，同比增长9.6%，非新冠收益同比增长13.1%；毛利同比增长12.1%至76.5亿元人民币；经调整EBITDA同比增长14.4%至80.0亿元人民币。公司新增151个综合项目，综合项目总数达817个，成为业内最大的复杂分子管线之一。按地区划分，北美市场收入占比最高，同比增长32.5%，中国市场收入占比约15.1%，欧洲市场收入占比约23.2%。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.